Antibiotic therapy for diabetic foot infections: Comparison of cephalosporines with chinolones

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 17, Issue 3, 2004, Pages 156-162

  Lobmann, R ^a   Ambrosch, A ^b   Seewald, M ^c   Dietlein, M ^d   Zink, K ^e   Kullmann, K H ^f   Lehnert, Hendrik ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Department of Women's Diseases   (Germany)

^c Institute of Medical Diagnostics   (Germany)

^d Krankenhaus Haunstetten   (Germany)

^e Diabetes Klinik Bad Mergentheim   (Germany)

^f ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Antibiotic treatment; Cephalosporines; Chinolones; Diabetic foot

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; FOOT DISEASE; FOOT RADIOGRAPHY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STANDARDIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEFTRIAXONE; CIPROFLOXACIN; DIABETIC FOOT; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

NEGIBACTERIA; POSIBACTERIA;

EID: 4344712892     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Diabetes Care and Research Group in Europe: The Saint Vincent Declaration. Diabet. Med. 7: 360, 1990.
2. Armstrong D.G., Lavery L.A., Harkless L.B., van Houtum W.H.: Amputation and reamputation of the diabetic foot. J. Am. Podiatr. Med. Assoc. 87: 255-259, 1997.
3. Grayson M.L.: Diabetic foot infections. Antimicrobial therapy. Infect. Dis. Clin. North. Am. 9: 143-161, 1995.
4. Goldstein E.J., Citron D.M., Nesbit C.A.: Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 19: 638-641, 1996.
5. Frykberg R.G.: Diabetic foot infections: evaluation and management. Adv. Wound Care 11: 329-331, 1998.
6. Caballero E., Frykberg R.G.: Diabetic foot infections. J. Foot Ankle Surg. 37: 248-255, 1998.
7. Marhoffer W., Stein M., Maeser E., Federlin K.: Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 15: 256-260, 1992.
8. Marhoffer W., Stein M., Schleinkofer L., Federlin K.: Evidence of ex vivo and in vitro impaired neutrophil oxidative burst and phagocytic capacity in type 1 diabetes mellitus. Diabetes Res. Clin. Pract. 19: 183-188, 1993.
9. Wagner F.W.: The dysvascular foot: a system for diagnosis and treatment. Foot Ancle 2: 64-122, 1981.
10. Caputo G.M., Cavanagh P.R., Ulbrecht J.S., Gibbons G.W., Karchmer A.W.: Assesment and management of foot disease in patients with diabetes. N. Engl. J. Med. 331: 854-860, 1994.
11. Joshi N., Caputo G.M., Weitekamp M.R., Karchmer A.W.: Infections in patients with diabetes mellitus. N. Engl. J Med. 341: 1906-1912, 1999.
12. Lode H., Hoffken G., Boeckk M., Deppermann N., Borner K., Koeppe P.: Quinolone pharmacokinetics and metabolism. J. Antimicrob. Chemother. 26 (Suppl B): 41-49, 1990.
13. Sorgel F., Kinzig M.: Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition. Am. J. Med. 94: 44S-55S, 1993.
14. Gentry L.O.: Review of quinolories in the treatment of infections of the skin and skin structure. J. Antimicrob. Chemother. 28 (Suppl C): 97-110, 1991.
15. Hoogkamp-Korstanje J.A., van Bottenburg H.A., van Bruggen J., Davidson J.S., Detmar S.J., de Graaf W., Rijnks J., Ypma U., de Zwart D.F.: Treatment of chronic osteomyelitis with ciprofloxacin. J. Antimicrob. Chemother. 23: 427-432, 1989.
16. Dellamonica P., Bernard E., Etesse H., Garraffo R., Drugeon H.B.: Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. Eur. J. Clin. Microbiol. Infect. Dis. 8: 1024-1030, 1989.
17. Pellizzer G., Strazzabosco M., Presi S., Furlan F., Lora L., Benedetti P., Bonato M., Erle G., de Lalla F.: Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet. Med. 18: 822-827, 2001.
18. Ragnarson T.G., Apelqvist J.: Health-related quality of life in patients with diabetes mellitus and foot ulcers. J. Diabetes Complications 14: 235-241, 2000.
19. Ragnarson T.G., Apelqvist J.: Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 44: 2077-2087, 2001.
20. Apelqvist J., Bakker K., van Houtum W.H., Nabuurs-Franssen M.H., Schaper N.C.: International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab. Res. Rev. 16 (Suppl 1): S84-S92, 2000.
21. Levin M.E.: Diabetic foot wounds: pathogenesis and management. Adv. Wound Care 10: 24-30, 1997.
22. Levin M.E.: Prevention and treatment of diabetic foot wounds. J. Wound Ostomy Continence Nurs. 25: 129-146, 1998.
23. Boulton A.J., Meneses P., Ennis W.J.: Diabetic foot ulcers: A framework for prevention and care. Wound Repair Regen. 7: 7-16, 1999.
24. Oyibo S.O., Abouaesha F., Connor H., Boulton A.J.: The diabetic foot 2000. Diabet. Med. 17: 875-876, 2000.